People · Operator
Named in public records as an officer, director or promoter · active 2012–2012 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Intercept Pharmaceuticals Inc | — | Biotechnology | Series B | $45.0M | $1.2B | 2012 |
Barbara E. Duncan at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Barbara E. Duncan on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Jonathan T. Silverstein | 1 | 3 |
| David E Shapiro | 1 | 2 |
| Paolo E. Fundaro | 1 | 1 |
| Mark E. Pruzanski | 1 | 1 |
| Nicole E. Williams | 1 | 1 |
| Lorenzo E. Tallarigo | 1 | 1 |
| Luciano E. Adorini | 1 | 1 |
| Klaus T. Veltinger | 1 | 1 |
| Klaus T. Veitinger | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.